Intercept Pharma (ICPT) Tops Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update
May 8, 2018 7:05 AM EDTWorldwide Ocaliva net sales of $35.2 million in the first quarter of 20182018 worldwide Ocaliva net sales currently expected to be between $170 million and $185 millionContinuing to advance leading NASH Phase 3 program: REGENERATE trial in non-cirrhotic NASH patients with liver fibrosis on track to report data in the first half of 2019; REVERSE trial in NASH patients with compensated cirrhosis continues to enroll patientsConference call scheduled for 8:30 a.m. ET today
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.... More
